
Kerala HC orders government to tackle exorbitant pricing of breast cancer drugs
The story in brief
The Kerala High Court ruled that the government must address exorbitant pricing of abemaciclib and ribociclib, which target CDK4/6 proteins in breast cancer. Despite generating $19.6 billion and $12.7 billion in sales, the medicines remain patented, limiting generic competition. Patients may not see immediate relief as the government lacks a timeline or clear responsibility.